Epidermal growth factor receptor (EGFR) is a major molecular for target therapy. The epidermal growth factor receptor tyrosine kinase inhibitors (TKIs), gefitinib (Iressa) and erlotinib (Tarceva), are two prospective agents towards non-small cell lung cancer (NSCLC). Multi-center clinical studies showed that there were obvious differences between individuals by the treatment of EGFR-TKIs. EGFR status is the major factor that influences the outcome for the treatment by TKI. Exon mutations and amplification of EGFR molecule are the critical factors that predict good response to TKIs. On the other hand, KRAS mutations indicate the resistant to the TKIs.
近几年，表皮生长因子受体（epidermal growth factor receptor, EGFR）是肿瘤学药物研发的一个重要靶点。EGFR的小分子抑制剂（tyrosine kinase inhibitors, TKIs）成为目前非小细胞肺癌（non-small cell lung cancer, NSCLC）靶向治疗的热点。临床研究表明，EGFR-TKIs的临床疗效存在明显的个体差异，EGFR分子的存在状态影响TKI的疗效。EGFR外显子突变、EGFR拷贝数增加的患者对TKI的疗效较好，而存在KRAS突变患者提示对TKI耐药。